Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02240706 · ClinicalTrials.gov registry record · Phase 2
Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT02240706 is a Phase 2 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 27 participants.
The verdict
NCT02240706, a Phase 2 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
Phase I: To investigate maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics, exploratory biomarker and efficacy of BI 836858 monotherapy in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS) with symptomatic anemia. Phase II: To investigate safety and efficacy of BI 836858 plus Best Supportive Care compared to Best Supportive Care alone in low or intermediate-1 risk MDS patients with symptomatic anemia.
Interventions
- DRUG BI 836858
- PROCEDURE Best Supportive Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2015-01-22 |
| Est. Completion | 2019-11-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02240706
The ClinicalTrials.gov registry entry for NCT02240706 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BI 836858 is the first listed.
NCT02240706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02240706 about?
NCT02240706 is a clinical study titled "Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes". Phase I: To investigate maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics, exploratory biomarker and efficacy of BI 836858 monotherapy in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS) with symptomatic anemia. Phase II: To investigate safety and effica...
What is the current status of trial NCT02240706?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2015-01-22. Estimated completion is 2019-11-18.
What interventions are being tested in trial NCT02240706?
The interventions under investigation include: BI 836858 (DRUG), Best Supportive Care (PROCEDURE).
Who is sponsoring clinical trial NCT02240706?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.